Published: January 22, 2024 · Last reviewed: May 1, 2026
Last updated: February 2026
AAMI TIR57:2016 (R2023) is a Technical Information Report offering principles for medical device cybersecurity risk management. It provides a practical framework for integrating cybersecurity risk analysis into existing quality management systems, particularly those aligned with ISO 14971. This consensus standard guides medical device manufacturers in developing repeatable processes for threat modeling, risk assessment, control implementation, and documentation, which matters for demonstrating compliance with the FDA's February 2026 premarket cybersecurity guidance.
Key Takeaways
- TIR57 is an implementation guide for cybersecurity risk management in the context of ISO 14971-use it to make your security risk work audit- and review-ready.
- The goal is traceability: threats → security requirements → implemented controls → verification evidence → residual risk rationale.
- Premarket success depends on artifacts, not intentions-documented processes and objective evidence matter most.
- Postmarket is part of risk control: monitoring, coordinated vulnerability disclosure, and secure update/patch capability are expected behaviors, not optional extras.
Table of Contents
- Key Takeaways
- What is AAMI TIR57 (and what it isn’t)?
- Where TIR57 fits in an FDA-ready cybersecurity program
- How to run a TIR57-aligned cybersecurity risk assessment (practical workflow)
- Common pitfalls we see (and how to avoid them)
- Recommended references
- AAMI TIR57 and Medical Device Cybersecurity FAQs
Why this matters
AAMI TIR57 (R2023) matters because it provides a critical framework for integrating cybersecurity risk analysis into existing quality management systems, particularly those aligned with ISO 14971. This standard directly supports manufacturers in demonstrating compliance with the FDA's "Cybersecurity in Medical Devices" Final Guidance, dated February 3, 2026. The guidance emphasizes the necessity of a disciplined, traceable risk approach in premarket submissions for medical devices. TIR57 helps operationalize the 'how' for what a solid cybersecurity story should include, as outlined by the FDA. By following TIR57 principles, manufacturers can develop repeatable processes for threat modeling, risk assessment, control implementation, and documentation. This alignment with consensus standards like ISO 14971, IEC 62304, and IEC 81001-5-1 is crucial for achieving premarket success and ensuring objective evidence of security measures. Without such a framework, manufacturers risk significant delays or rejection during regulatory review.
What is AAMI TIR57 (and what it isn’t)?
AAMI TIR57:2016 (R2023) is a Technical Information Report titled Principles for medical device security - Risk management. You can purchase it from the AAMI/ANSI webstore.
TIR57 is not a regulation. It’s not a one-page checklist. It’s a practical framework for running a repeatable cybersecurity risk management process that integrates with:
- ISO 14971 (safety risk management),
- software lifecycle practices (e.g., IEC 62304), and
- security lifecycle practices (e.g., IEC 81001-5-1 / secure product development expectations).
Why it matters: FDA has recognized AAMI TIR57 as a consensus standard, and reviewers routinely look for the kind of disciplined, traceable risk approach that TIR57 promotes.
Where TIR57 fits in an FDA-ready cybersecurity program
If you want a simple mental model: FDA guidance describes what a solid cybersecurity story should include. TIR57 helps you execute the how-especially the mechanics of risk analysis, risk controls, and documentation.
In practice, TIR57 aligns well with a Secure Product Development Framework (SPDF) and supports the kind of evidence FDA expects in premarket submissions for devices with cybersecurity risk.
If you need help assembling a submission-ready package (SPDF, threat modeling, SBOM, and test evidence), see our FDA Premarket Cybersecurity Services.
How to run a TIR57-aligned cybersecurity risk assessment (practical workflow)
1) Define scope and intended use (including the “real” environment)
Start with what your device actually is in the field: connectivity, users, privileges, update paths, cloud dependencies, accessories, mobile apps, and the clinical workflow. Cyber risk changes dramatically depending on whether your device is isolated, hospital-networked, or cloud-connected.
Output: a clear scope statement and architecture/context description you can reuse in your risk file and premarket documentation.
2) Build a threat model that matches your architecture
TIR57 works best when your risk analysis is grounded in a threat model. Identify trust boundaries, data flows, privileged functions, and credible threat scenarios (e.g., unauthorized remote access, tampering, denial-of-service affecting essential performance).
Output: threat model + threat scenarios tied to architecture and intended use.
Need a structured approach? See Medical Device Threat Modeling Services.
3) Identify hazards and hazardous situations-including cybersecurity-driven ones
In a medical device context, cybersecurity events matter because they can impact:
- safety (patient harm),
- essential performance (loss or degradation of critical function),
- effectiveness (incorrect output or therapy), and
- confidentiality/integrity/availability of data and system behavior.
Output: a cybersecurity hazard list that can be incorporated into (or linked with) your ISO 14971 risk management file.
4) Analyze risk using defined criteria (not gut feel)
Define your scoring/acceptance criteria up front. Then assess each scenario using consistent logic. Good analyses distinguish between:
- likelihood drivers (exposure, attack feasibility, required access, complexity), and
- impact drivers (patient harm severity, essential performance degradation, clinical detectability, recovery time).
Output: risk ratings with documented rationale that a reviewer can follow.
5) Select risk controls that are testable (and don’t break clinical use)
Controls should be specific, implementable, and verifiable. Examples include:
- authentication/authorization for privileged functions,
- secure update mechanisms and rollback protections,
- encryption and key management appropriate to the threat model,
- logging and event detection aligned to safety impact,
- hardening and secure configuration baselines,
- software composition governance (SBOM + component control),
- secure-by-design development practices (code review, SAST/DAST where appropriate).
Output: security requirements and design controls that map to each mitigated risk.
For SBOM creation and ongoing component tracking, see FDA-Compliant SBOM Services for MedTech.
6) Generate objective evidence: verification, validation, and security testing
This is where many submissions get weak: controls are described, but not proven. Build evidence that the control exists and works under expected conditions. Common evidence includes:
- requirements-to-test traceability,
- security verification results (including negative testing),
- penetration testing focused on realistic attack paths,
- vulnerability analysis of third-party components, and
- secure update and recovery testing.
See also: MedTech Cyber Standards Every Device Team Must Know, IEC 80001-1: Enhancing Medical Device Cybersecurity, and MDCG 2019-16 & MedTech Cybersecurity.
Output: test plans and reports that support your cybersecurity claims.
Need FDA-aligned testing? See FDA-Compliant Vulnerability & Penetration Testing.
7) Document residual risk and your justification
Residual risk decisions should be explicit: what remains, why it is acceptable, and what monitoring/response controls are in place. If you rely on user/administrator actions, include realistic labeling and instructions-not vague warnings.
Output: residual risk statements tied to evidence and postmarket controls.
8) Make postmarket part of the plan, not an afterthought
TIR57 emphasizes lifecycle risk management. That means you should plan for:
- coordinated vulnerability disclosure (intake, triage, response timelines),
- monitoring for newly disclosed component vulnerabilities,
- patch development and deployment processes,
- communication to customers and regulators when appropriate, and
- periodic reassessment when the environment changes.
Output: vulnerability management procedures and update/patch governance that you can defend in audits and inspections.
For ongoing lifecycle support, see FDA Postmarket Cybersecurity Management Services.
Common pitfalls we see (and how to avoid them)
- Threat model is missing or generic → Build it from your real architecture and clinical workflow.
- Controls aren’t traceable to risks → Maintain a simple mapping: scenario → requirement → control → test evidence.
- Testing is “security theater” → Focus on realistic attack paths and document what you did and didn’t test.
- Residual risk is hand-waved → Write the rationale so a third party can follow it without assumptions.
- Postmarket plan is vague → Define intake, triage, remediation, and customer communication steps.
Recommended references
- FDA: Cybersecurity in Medical Devices (Final Guidance, February 2026)
- FDA Recognized Consensus Standard: AAMI TIR57
- AAMI/ANSI Webstore: AAMI TIR57:2016 (R2023)
- ISO 14971 and AAMI TIR57: How they work together (Blue Goat Cyber)
How Blue Goat approaches this
Blue Goat Cyber operationalizes AAMI TIR57 (R2023) principles to streamline your medical device cybersecurity risk management. We provide direct support in conducting thorough cybersecurity risk assessments, developing threat models, and defining security controls that align with your product development lifecycle. Our methodology ensures traceability from identified threats to implemented safeguards, generating the essential artifacts required for regulatory submissions. We help you build a "cybersecurity story" that meets the stringent expectations of the FDA, integrating smoothly with your existing ISO 14971 processes. Our team, with expertise including CISSP and ex-military red team experience, delivers practical, actionable strategies. We prepare your documentation for premarket submissions, reducing the likelihood of deficiencies. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more about our specialized support for FDA premarket submissions: https://www.bluegoatcyber.com/services/fda-premarket-cybersecurity-services.
AAMI TIR57 and Medical Device Cybersecurity FAQs
Is AAMI TIR57 required by FDA?
No-TIR57 is not a regulation. But it’s widely used because it provides a disciplined, reviewable way to manage cybersecurity risk using a risk management structure that regulators understand.
How is TIR57 different from FDA cybersecurity guidance?
FDA guidance explains what FDA recommends for device cybersecurity design, labeling, and premarket documentation. TIR57 provides practical methods to perform cybersecurity risk management in a structured, ISO 14971-aligned way.
How does TIR57 align with ISO 14971?
TIR57 fits cybersecurity risk work into a broader medical device risk management system: identify hazards, estimate and evaluate risk, implement controls, verify effectiveness, and document residual risk-using cybersecurity-appropriate inputs like threat models and vulnerability analysis.
What evidence should we have if we say we follow TIR57?
At a minimum: threat model, security requirements, risk control mapping, verification/validation results, and residual risk justification. Strong submissions also show postmarket monitoring, coordinated vulnerability disclosure, and update/patch capability.
What’s the fastest way to apply TIR57 to a legacy device?
Start with architecture and data flows, then run a focused threat model to identify the highest-impact scenarios. Prioritize compensating controls and update pathways you can realistically support, then build a minimal-but-traceable evidence set around those decisions.
Conclusion
AAMI TIR57 (R2023) is valuable because it turns “do cybersecurity” into a repeatable risk management process with artifacts you can defend. If your goal is an FDA-ready cybersecurity story, TIR57 helps you produce the traceable evidence reviewers and auditors can follow-without reinventing your quality system.
Related: For a 2026 submission, TIR57 alone is no longer enough - see AAMI TIR57 vs TIR97 vs SW96 for how the three documents stack and which one the FDA actually recognizes. For the pre- vs postmarket split specifically, our AAMI TIR57 vs TIR97 comparison guide shows how to carry the same risk file across the device lifecycle.
Book a Discovery Session
If you want help building a TIR57-aligned, submission-ready cybersecurity package (threat modeling, SBOM, testing evidence, and documentation), we can help.
FAQ
Is AAMI TIR57 required by the FDA?
No, TIR57 is not a regulation. However, the FDA recognizes it as a consensus standard, making it a highly useful framework for demonstrating a disciplined and reviewable approach to cybersecurity risk management that aligns with regulatory expectations.
How is TIR57 different from FDA cybersecurity guidance?
FDA guidance outlines the agency's recommendations for medical device cybersecurity design, labeling, and premarket documentation. TIR57 offers practical methodologies to conduct cybersecurity risk management in a structured, ISO 14971-aligned manner.
How does TIR57 align with ISO 14971?
TIR57 integrates cybersecurity risk into the broader medical device risk management system. It guides users through identifying hazards, estimating and evaluating risk, implementing controls, verifying effectiveness, and documenting residual risk, using cybersecurity-specific inputs like threat models and vulnerability analysis.
What evidence should we have if we say we follow TIR57?
Key evidence includes a threat model, defined security requirements, a clear risk-to-control mapping, verification and validation results, and a justification of residual risk. Strong submissions also incorporate plans for postmarket monitoring, coordinated vulnerability disclosure, and secure update/patch capabilities.
What’s the fastest way to apply TIR57 to a legacy device?
For legacy devices, begin by mapping the architecture and data flows, then conduct a focused threat model to identify high-impact scenarios. Prioritize implementable compensating controls and update pathways, then build a minimal yet traceable evidence set to support these decisions.
About the author
Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.
Continue the Cybersecurity risk management series
Dive deeper with these companion articles:
Sources & references
Primary sources cited in this article. Links open in a new tab.